杨宁介入医学网

肝包膜下肝癌消融主要有三点...

现行的原发性肝脏恶性肿瘤(如肝癌)的治疗指南中，肝细胞癌(HCC)，肝内胆管癌(ICC)和肝转移，如结直肠癌(mCRC)，建议将经动脉放疗性栓塞 (TARE，也称为选择性内放射治疗SIRT) 作为一种可选的治疗方式，用于不适合手术或消融治疗的肝占导性疾病患者，或在接受...

TACE术后病人的随访包括临床和影像 BCLC staging and treatment strategy, 2012 Forner, et al. Lancet. 2012 Mar 31;379(9822):1245-55. 为什么说TACE是中期肝癌的标准治疗 *P values refer to cumulative meta-analysis of five and six studies, respecti ...

尽管标准化的HAIC技术是评估HAIC安全性和疗效的重要因素，但HAIC技术的异质性仍然是评价这一技术的争议之一。 许多HAI化疗技术可以通过放置一个输液港-导管系统来进行。 在过去，输液导管是通过剖腹手术植入的，但患者暴露于与剖腹手术和全身麻醉相关的风险。...

简介 Hepatic artery infusion chemotherapy (HAIC) is a treatment modality for advanced hepatocellular carcinoma (HCC). 肝动脉输注化疗(HAIC)是治疗晚期肝癌(HCC)的一种治疗方式。 HAIC entails infusing chemotherapeutic agents directly into hepat...

The following characteristics of HAIC render it a suitable candidate for combination with other antineoplastic agents for advanced HCC: it is associated with fewer systemic adverse events compared with intravenous chemotherapy, and its cyt...

Lack of Industry Incentive for Conducting Trials 开展试验缺乏行业激励 The patents for the main chemotherapeutic agents used in HAIC, including cisplatin, oxaliplatin, 5-FU, and epirubicin, have expired, thus weakening the motivation for th...

Insufficient Technical Standardization Techniques and protocols for HAIC have yet to be standardized. HAIC的技术和方案尚未标准化。 The efficacy and safety of HAIC depend substantially on the quality of vascular redistribution. HAIC的有效性...

Two different percutaneous arterial access approaches have been used for HAIC: the first approach entails the use of implantable port-catheter systems, and the second approach involves repeated hepatic artery catheterization. 两种不同的经...

A standard chemotherapy regimen for HAIC has yet to be established, increasing the challenge of interpreting trial results. HAIC的标准化疗方案尚未建立，这增加了解释试验结果的挑战。 Cisplatin and 5-FU were the most commonly used chemotherap...